Тема: КЛИНИКО-БИОХИМИЧЕСКИЕ КОРРЕЛЯТЫ НЕЙРОКОГНИТИВНОГО ДЕФИЦИТА ПРИ ШИЗОФРЕНИИ

1. Bleuler E. Dementia praecox or the group of schizophrenias. – 1950. – P.45-49, 71-73.
2. Keefe R. S. Cognitive deficits in patients with schizophrenia: effects and treatment //The Journal of clinical psychiatry. – 2007. – Т. 68. – P. 8-13.
3. Harris J. G., Minassian A., Perry W. Stability of attention deficits in schizophrenia //Schizophrenia research. – 2007. – Т. 91. – №. 1-3. – P. 107-111.
4. Bowie C. R., Harvey P. D. Cognitive deficits and functional outcome in schizophrenia //Neuropsychiatric disease and treatment. – 2006. – Т. 2. – №. 4. – P. 531.
5. Harvey P. D., Koren, D., Reichenberg, A. et al. Negative symptoms and cognitive deficits: what is the nature of their relationship? //Schizophrenia bulletin. – 2006. – Т. 32. – №. 2. – P. 250-258.
6. Putnam K. M., Harvey, P. D., Parrella, M. et al. Symptom stability in geriatric chronic schizophrenic inpatients: a one-year follow-up study //Biological Psychiatry. – 1996. – Т. 39. – №. 2. – P. 92-99.
7. Davidson M., Harvey, P. D., Powchik, P. et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients //The American journal of psychiatry. – 1995. – Т. 152. – №. 2. – P. 197.
8. Meyer U., Schwarz M. J., Müller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond //Pharmacology & therapeutics. – 2011. – Т. 132. – №. 1. – P. 96-110.
9. Penadés R., García-Rizo C., Bioque M. et al. The search for new biomarkers for cognition in schizophrenia //Schizophrenia research: cognition. – 2015. – Т. 2. – №. 4. – P. 172-178.
10. Green M. J., Matheson, S. L., Shepherd, A. et al. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis //Molecular psychiatry. – 2011. – Т. 16. – №. 9. – P. 960-972.
11. Gottesman I. I., Gould T. D. The endophenotype concept in psychiatry: etymology and strategic intentions //American journal of psychiatry. – 2003. – Т. 160. – №. 4. – P. 636-645.
12. Luperdi S. C., Tabarés-Seisdedos, R., Livianos, L. et al. Neurocognitive endophenotypes in schizophrenia and bipolar disorder: A systematic review of longitudinal family studies //Schizophrenia research. – 2019. – P. 203-207
13. Gur R. E., Calkins, M. E., Gur, R. C. et al. The consortium on the genetics of schizophrenia: neurocognitive endophenotypes //Schizophrenia bulletin. – 2007. – Т. 33. – №. 1. – P. 49-68
14. Ting C., Rajji T. K., Ismail Z. et al. Differentiating the cognitive profile of schizophrenia from that of Alzheimer disease and depression in late life //PloS one. – 2010. – Т. 5. – №. 4. – P. 13-19
15. Keefe R. S., Bilder R. M., Harvey P. D. et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. //Neuropsychopharmacology. – 2006. – Т. 31. – №. 9. – P .2033-2046.
16. Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh: E. & S. //Livingstone; 1919. – P. 10-13
17. Addington J., Brooks B. L., Addington D. Cognitive functioning in first episode psychosis: Initial presentation. //Schizophrenia Research. – 2003. – Т. 62. – №. 1-2. – Р. 59-64.
18. Albus M., Hubmann W., Ehrenberg C. H. et al. Neuro- psychological impairment in first episode and chronic schizophrenic patients. //European Archives of Psychiatry and Clinical Neuroscience. – 1996. – Т. 246. – №. 5. – Р. 249-255.
19. Bora E., Lin A., Wood S. J. et al. Cognitive deficits in youth with familial and clinical high risk to psychosis: A systematic review and meta-analysis. //Acta PsychiatricaScandinavica. – 2014. – Т. 130. – №. 1. – Р. 1-15.
20. Kuha A., Tuulio-Henriksson A., Eerola M. et al. Impaired executive performance in healthy siblings of schizophrenia patients in a population-based study. //Schizophrenia Research. – 2007. – Т. 92. – №. 1-2. – P. 142-150
21. Nuechterlein K. H., Dawson M. E., Gitlin M. et al. Developmental processes in schizophrenic disorders: Longitudinal studies of vulner- ability and stress. //Schizophrenia Bulletin. – 1992. – Т. 18. – №. 3 – P. 387-425
22. Reichenberg A. The assessment of neuropsychological functioning in schizophrenia. //Dialogues in Clinical Neuroscience. – 2010. – Т. 12. – №. 3. – P. 383-392
23. Green M. F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. //The Journal of Clinical Psychiatry. – 2006. – Т. 67. – Р. 12-16
24. Heinrichs R. W., Zakzanis K. K. Neurocognitive deficit in schizophrenia. //A Quantitative Review of the Evidence Neuropsychology. – 1998. – Т. 12. – №. 3. – Р. 426-445
25. Dominguez M. G., Viechtbauer W., Simons C. J. et al. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associa- tions. //Psychological Bulletin. – 2009. – Т. 135. – №. 1. – P.157-171.
26. Goldberg T. E., Ragland J. D., Torrey E. F. et al. Neuro- psychological assessment of monozygotic twins discordant for schizophrenia. //Archives of General Psychiatry. – 1990. – Т. 47. – №. 11. – P. 1066-1072
27. Burton C. Z., Twamley E. W. Neurocognitive insight, treatment utilization, and cognitive training outcomes in schizophrenia. //Schizophrenia Research. – 2015. – Т. 161. – №. 2-3. – P. 399-402
28. Bell M. D., Bryson G. Work rehabilitation in schizophrenia: Does cognitive impairment limit improvement? //Schizophrenia Bulletin. – 2001. – Т. 27. – №. 2. –P. 269-279
29. Green M. F., Kern R. S., Braff D. L. et al. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the “right stuff”? //Schizophrenia Bulletin. – 2000. – Т. 26. – №. 1. – P. 119-136
30. Wykes T., Reeder C., Williams C. et al. Are the effects of cognitive remediation therapy (CRT) durable? Results from an exploratory trial in schizophrenia. //Schizophrenia Research. – 2003. – Т. 61. – №. 2-3. – P. 163-174
31. CerveraEnguix S., Seva Fernandez A. Esquizofreniaresistente al tratamientofarmacológico //ActasEspañolas de Psiquiatria. – 2006. – Т. 34. – №. 1. – P. 48-54
32. González-Blanch C., Crespo-Facorro B., Alvarez-Jiménez M. et al. Pretreatment predictors of cognitive deficits in early psychosis. //Psychological Medicine. – 2008. – Т. 38. – №. 5. – P. 737-746
33. Balanzá-Martínez V., Rubio C., Selva-Vera G. et al. Neurocognitive endophenotypes (endophenocognitypes) from studies of relatives of bipolar disorder subjects: A systematic review. //Neuroscience and Biobehavioral Reviews. – 2008. – Т. 32. – №. 8. – P. 1426-1438.
34. Schaefer J., Giangrande E., Weinberger D. R. et al. The global cognitive impair- ment in schizophrenia: Consistence over decades and around the world. //Schizophrenia Research. – 2013. – Т. 150. – №. 1. – С. 42-50.
35. Crespo-Farroco B., Rodríguez-Sánchez J.M., Barbás-Calvo P. et al. Cognitive functions altered and preserved in schizophrenia [Funcionescogni- tivasalteradas y preservadasen la esquizofrenia]. In: Rojo-Rodes E, Tabarés-Seisdedos R, editors. Manual práctico de cogniciónen la esquizofrenia y el trastorno bipolar. //Barcelona: Ars Medica. – 2007. – P. 13-33
36. Kircher T., Whitney C., Krings T. et al. Hippocampal dysfunction during free word association in male patients with schizophrenia. //Schizophrenia Research. – 2008. – Т. 101. – №. 1-3. – С. 242-255.
37. Flashman L. A., Green M .F. Review of cognition and brain structure in schizophrenia: Profiles, longitudinal course, and effects of treatment. //The Psychiatric Clinics of North America. – 2004. – Т. 27. – №. 1. – P. 1-18
38. Lee J., Park S.. Working memory impairments in schizophrenia: A meta-analysis. Journal of Abnormal Psychology. – 2005. – Т. 114. – №. 4. – P. 599-611
39. Brébion G., Amador X., Smith M. J. et al. Mechanisms underlying memory impair- ment in schizophrenia. //Psychological Medicine. – 1997. – Т. 27. – №. 2. –: P. 383-393
40. Hartman M., Steketee M. C., Silva S. et al. Working memory and schizo- phrenia: Evidence for slowed encoding. //Schizophrenia Research. – 2003. – Т. 59. – №. 2-3. – P. 99-113
41. Green M. F., Nuechterlein K. H. The MATRICS initiative: Developing a consensus cognitive battery for clinical trials. //Schizophrenia Research. – 2004. – P. 1-3
42. Nuechterlein K. H., Barch D. M., Gold J. M. et al. Identification of separable cognitive factors in schizophrenia. //Schizophrenia. – 2004. – Т. 72. – №. 1. – P. 29-39
43. Саркисян Г. Р., Гурович И. Я., Киф Р. С. Нормативные данные для российской популяции и стандартизация шкалы «Краткая оценка когнитивных функций у пациентов с шизофренией»(BACS) //Социальная и клиническая психиатрия. – 2010. – Т. 20. – №. 3. - С.15-25
44. Keefe R. S. E., Harvey, P. D., Goldberg, T. E. et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) //Schizophrenia research. – 2008. – Т. 102. – №. 1-3. – P. 108-115.
45. Аведисова А. С., Вериго Н. Н. Синдром дефицита, вызванного нейролептиком //Рос. психиатр. журн. – 2001. – №. 5. – С. 43-46.
46. Алфимова М. В. Наследственные факторы в нарушениях познавательных процессов при шизофрении // М. – 2006. – С. 25-32.
47. Geddes J., Freemantle, N., Harrison, P. et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis //Bmj. – 2000. – Т. 321. – №. 7273. – P. 1371-1376.
48. Hoff A. L., Harris D., Faustman W. O. et al. A neuropsychological study of early onset schizophrenia //Schizophrenia research. – 1996. – Т. 20. – №. 1-2. – P. 21-28.
49. Tuulio-Henriksson A., Partonen T., Suvisaari J. et al. Age at onset and cognitive functioning in schizophrenia //The British Journal of Psychiatry. – 2004. – Т. 185. – №. 3. – P. 215-219.
50. Rodrigue A. L., McDowell J. E., Tandon N. et al. Multivariate relationships between cognition and brain anatomy across the psychosis spectrum //Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. – 2018. – Т. 3. – №. 12. – P. 992-1002.
51. Дорофейкова М. В. Структура и факторы развития когнитивных расстройств у больных шизофренией :дис. – –психиатрия/Дорофейкова Мария Владимировна, 2017. - С. 21-22
52. Петрова Н. Н., Дорофейкова М. В., Воинкова Е. Е. Когнитивные нарушения у больных шизофренией на разных этапах течения заболевания //Журнал неврологии и психиатрии им. СС Корсакова. – 2016. – Т. 116. – №. 4. – С. 10-15
53. Дорофейкова М. В., Петрова Н. Н. Нарушения когнитивных функций при шизофрении и их коррекция //Современная терапия психических расстройств. – 2015. – №. 1. – С. 2-9.
54. Kurtz M. M., Mueser K. T. A meta-analysis of controlled research on social skills training for schizophrenia //Journal of consulting and clinical psychology. – 2008. – Т. 76. – №. 3. – Р. 491-499.
55. Дорофейкова М. В. Когнитивные нарушения и клинико-лабораторные характеристики у больных шизофренией //Обозрение психиатрии и медицинской психологии имени ВМ Бехтерева. – 2017. – №. 1. – С. 37-44.
56. Milev, P., Ho B.C., Arndt, S. et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. //American Journal of Psychiatry. – 2005. – Т. 162. – №. 3. – Р. 495-506.
57. Rothermundt, M., Missler, U., Arolt, V. et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology //Molecular psychiatry. – 2001. – Т. 6. – №. 4. – Р. 445-449.
58. Streitbürger, D.-P., Arelin, K., Kratzsch, J. et al. Validating serum S100B and neuron-specific enolase as biomarkers for the human brain – a combined serum, gene expression and MRI study //PloS one. – 2012. – Т. 7. – №. 8. – P. 14-19.
59. Дорофейкова М. В. Когнитивные нарушения и клинико-лабораторные характеристики у больных шизофренией //Обозрение психиатрии и медицинской психологии имени ВМ Бехтерева. – 2017. – №. 1. – С. 37-44.
60. Незнанов Н. Г., Дорофейкова М. В., Петрова Н. Н. Особенности течения шизофрении и лабораторные маркеры крови //ПСИХИАТРИЯ И ПСИХОФАРМАКОТЕРАПИ. – 2017. – Т. 19. – №. 2. – С. 19-23.
61. Dickerson, F., Stallings, C., Origoni, A. et al. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia //Schizophrenia research. – 2007. – Т. 93. – №. 1-3. – С. 261-265.
62. Asevedo, E., Gadelha, A., Noto, C. et al. 2013. Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia //Journal of psychiatric research. – 2013. – Т. 47. – №. 10. – С. 1376-1382.
63. Ritsner M. S., Strous R. D. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA //Journal of psychiatric research. – 2010. – Т. 44. – №. 2. – P. 75-80.
64. Bergemann, N., Mundt, C., Parzer, P. et al. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study //Schizophrenia research. – 2005. – Т. 74. – №. 2-3. – С. 125-134.
65. Ko, Y. H., Joe, S. H., Cho, W. et al. Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia //International journal of psychiatry in clinical practice. – 2006. – Т. 10. – №. 2. – С. 97-104.
66. Trivedi J. K. Cognitive deficits in psychiatric disorders: Current status //Indian journal of psychiatry. – 2006. – Т. 48. – №. 1. – С. 10.
67. Потапов А. В. и др. Ремиссии при шизофрении: результаты популяционного и фармакотерапевтического исследований //Социальная и клиническая психиатрия. – 2010. – Т. 20. – №. 3. - С.57-62
68. Dorofeikova M., Neznanov N., Petrova N. Cognitive deficit in patients with paranoid schizophrenia: its clinical and laboratory correlates //Psychiatry research. – 2018. – Т. 262. – С. 542-548.
69. White L., Harvey P. D., Opler L. et al. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia //Psychopathology. – 1997. – Т. 30. – №. 5. – С. 263-274.
70. Zhang B., Han, M., Tan, S. et al. Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients //Scientific reports. – 2017. – Т. 7. – №. 1. – С. 1-8.

Купить